Health Care
Syntara Limited (SNT)
Syntara Limited is a clinical-stage Australian biotechnology company developing drugs for diseases involving fibrosis and inflammation. Its lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently in a Phase 2 clinical trial for the bone marrow cancer myelofibrosis. The company is also exploring its drug candidates for other indications, including liver and pancreatic cancer.
Market Cap
A$56M
Shares on Issue
N/A
Price Chart
AI Analysis
As a clinical-stage biotech with a market cap of A$56M, Syntara's valuation is intrinsically tied to the future potential of its drug pipeline, not current revenue or earnings. The company, which recently rebranded from Pharmaxis Ltd, is focused on advancing its lead asset PXS-5505 through its Phase 2 myelofibrosis study. Like its peers, Syntara is capital-intensive and operates with a significant cash burn, relying on equity markets to fund its research and development, with its most recent capital raising extending its cash runway to support ongoing trials.
The company's growth outlook is dominated by a single major catalyst: the clinical trial results for PXS-5505. A positive data readout would be a transformative event, potentially leading to a pivotal Phase 3 trial and attracting lucrative licensing or partnership deals from major pharmaceutical companies. The strategic direction involves proving the drug's efficacy and safety in myelofibrosis to de-risk the asset, while also generating pre-clinical data for expansion into other high-value fibrotic cancer indications to broaden its long-term potential.
Bull Case
- • Positive Phase 2 data for PXS-5505 in myelofibrosis could demonstrate a significant clinical benefit and lead to a substantial re-rating of the company's valuation.
- • The novel mechanism of action (pan-LOX inhibition) could prove to be a breakthrough in treating fibrotic diseases, opening up a multi-billion dollar market opportunity.
- • A successful trial outcome could make Syntara an attractive acquisition target for a large pharmaceutical company seeking to bolster its oncology or fibrosis pipeline.
Bear Case
- • Clinical trial failure is the single biggest risk; negative or inconclusive data for PXS-5505 would severely impair the company's value and future prospects.
- • The company has a high cash burn rate and will likely require further dilutive capital raisings to fund more expensive late-stage clinical trials.
- • Even if successful, PXS-5505 will face a competitive landscape from existing and new therapies being developed for myelofibrosis by larger, better-funded companies.
Recent Announcements
Investor Presentation Euroz Hartleys Healthcare Forum
2026 Outlook Webinar Presentation
Application for quotation of securities - SNT
2026 Outlook Webinar and Q&A
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveSNTE, an ASX-listed commitments test entity, has released its quarterly cash flow report in Appendix 4C of the latest financial statements.
FAQs
What does SNT do?
Syntara is a clinical-stage biotechnology company focused on developing drugs to treat diseases involving fibrosis (scarring). Its lead program is a drug called PXS-5505, which is being tested in a clinical trial as a treatment for myelofibrosis, a rare type of bone marrow cancer.
Is SNT a good investment?
SNT is a speculative, high-risk, high-reward investment. Its potential success is almost entirely dependent on positive clinical trial outcomes. A successful trial could lead to very significant returns for shareholders, but a failed trial would likely result in a substantial loss of capital.
What drives SNT's share price?
The share price is primarily driven by clinical and corporate news flow. Key catalysts include announcements on patient recruitment, clinical trial data readouts, regulatory feedback from bodies like the US FDA, and corporate actions such as partnerships, licensing deals, or capital raisings.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.